Tesamorelin vs Ipamorelin: What Does the Research Say?

Tesamorelin vs Ipamorelin: What Does the Research Say?

By Medical Team of Generic Peptides

Tesamorelin and ipamorelin are often seen as interchangeable because both release growth hormone (GH). However, they are very different compounds. Tesamorelin is a GHRH analog created by modifying the body's own GHRH peptide sequence. Ipamorelin is designed to act like ghrelin, a hormone produced in the stomach. These compounds target different receptors and have different amounts of research and regulatory approval. See below for our comparison guide.

Tesamorelin vs Ipamorelin: Quick Comparison

What Is Tesamorelin?

Tesamorelin is a synthetic version of the 44-amino-acid sequence of human GHRH, modified with a trans-3-hexenoyl group attached to the first amino acid. This makes it resistant to the enzyme DPP-4, which breaks down natural GHRH quickly [1, 2].

Tesamorelin is currently the only GHRH analog approved by the FDA. It was approved in 2010 as Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Newer formulations are available, including Egrifta SV (2018) and Egrifta WR (2025). For more information on tesamorelin and the studies it has been part of, please see our tesamorelin research guide.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed by Novo Nordisk in the 1990s. It belongs to the group of peptides known as GHRPs, which includes GHRP-2, GHRP-6 and hexarelin. Ipamorelin became well known for its selectivity. In rat and pig studies, it released GH; in pig studies, there was no increase in ACTH or cortisol, even at very high doses [3].

It was tested in humans to treat postoperative ileus, but no clear benefit was seen in a Phase II study [4]. No further development has been reported, and it has never been approved as a drug.

How Do They Work? GHRH-R vs Ghrelin Receptor

Both compounds increase GH release from somatotroph cells in the pituitary gland, which raises IGF-1. However, they do this in different ways.

Tesamorelin binds to the GHRH-R. This causes an increase in intracellular cAMP, resulting in more GH being secreted and produced [5]. It remains subject to inhibition by somatostatin, so natural pulsatile release is maintained [6].

Ipamorelin binds to the GHS-R1a (the ghrelin receptor). This activates a different signaling pathway (phospholipase C and calcium). GHRPs also appear to counteract the inhibitory effects of somatostatin [5].

Because the two classes work through different mechanisms, using a GHRH analog alongside a GHRP leads to greater GH secretion. This was demonstrated in a clinical study of GHRH and GHRP-6 in 18 healthy men [7]. For more information on why CJC-1295 and ipamorelin are combined, see Why Researchers Pair CJC-1295 and Ipamorelin.

Ipamorelin vs Tesamorelin: Clinical Research

The main difference between these two compounds is the amount of research available in humans.

Tesamorelin has a large body of clinical research:

• Two Phase III studies were completed in more than 800 adults with HIV and excess abdominal fat. Tesamorelin reduced visceral fat by around 11–15% over 26 weeks, while those taking placebo had little change or even an increase [8, 9].
• In a randomized study in people with HIV and fatty liver disease, tesamorelin decreased liver fat over 12 months. Around a third of participants taking tesamorelin reached normal liver fat levels, compared with 4% on placebo [10].
• A 20-week study found small improvements in executive function tests in older adults with normal cognition or mild cognitive impairment [11].

This research was carried out in specific groups, mainly people with HIV.

Ipamorelin has very little research:

• GH release in rats and pigs; selectivity (no ACTH or cortisol rise) was shown in pigs [3].
• One pharmacology study in healthy volunteers showed how GH levels change after administration. It found that the half-life of ipamorelin is around 2 hours [12].
• A Phase II study in patients recovering from bowel surgery showed no significant improvement in gut recovery [4].

In summary, tesamorelin has been tested in large human studies, while ipamorelin has only been tested in animal studies and early trials.

Combining Tesamorelin and Ipamorelin

Many people search for a "tesamorelin ipamorelin blend." This is mainly because clinics promote it. The scientific rationale is that GHRH analogs and GHRPs are known to act synergistically [7].

Unfortunately, we couldn't find any controlled studies of these two compounds combined. Any claims are based on extrapolation. The most well-studied GHRH and GHRP combination is CJC-1295 and ipamorelin. For more information on this combination, please see our research overview. You can also view our Duo Blend CJC-1295/Ipamorelin.

Tesamorelin vs Sermorelin vs Ipamorelin

Tesamorelin is often compared with sermorelin and ipamorelin.

Sermorelin is the first 29 amino acids of GHRH. Like tesamorelin, it targets the GHRH-R, but it degrades quickly. It was approved by the FDA as Geref but was discontinued in 2008. See Sermorelin vs Tesamorelin for more information.

Tesamorelin is the full-length, stabilized form of GHRH and has the most research.

Ipamorelin targets a completely different receptor. See Ipamorelin vs Sermorelin for more information.

Sermorelin and tesamorelin are close relatives, while ipamorelin is the odd one out. For a broader understanding of how these compounds differ from GH itself, see Somatropin vs GH Secretagogues.

Safety: Side Effects Seen in Studies

Tesamorelin. The most common adverse events seen in Phase III studies were injection-site reactions, joint pain, limb pain, peripheral edema and muscle pain. Some participants had increased blood glucose and IGF-1. The product information contains warnings about glucose intolerance and elevated IGF-1 levels [2, 8, 9].

Ipamorelin. Side effects were similar to placebo in the Phase II surgery study [4]. As a ghrelin-receptor agonist, it could theoretically affect appetite. However, there are no long-term safety data in humans.

Neither compound has long-term safety data in healthy individuals.

FDA and WADA Status in 2026

• Tesamorelin: approved by the FDA only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta SV and Egrifta WR) [2, 13].
• Ipamorelin: not an approved drug. It does not appear on the FDA 503A bulks list or in any interim 503A category. In 2024, an FDA advisory committee voted against adding it. It is listed in Category 2 (significant safety risks) for 503B outsourcing facilities [14, 15].
• WADA: both are prohibited at all times (S2.2.4: GHRH and its analogs, GH secretagogues and their mimetics, and GHRPs) [16].

COA Information

These are very different compounds, so you would expect to see differences in their COAs for tesamorelin and ipamorelin:

• Mass spectrometry: tesamorelin should have a molecular weight of around 5,136 Da and ipamorelin around 712 Da. If they don't match, the compound is not what the label says it is.
• HPLC purity: percentage of the main peak, with the chromatogram provided.
• Batch number and date: should match the vial.

For more information on what each part of a peptide COA means, please see our guide to reading a peptide COA. Generic Peptides provides both of these compounds, along with many other GH research peptides, for laboratory research use only. Every batch comes with a COA.

FAQ

What is the main difference between tesamorelin and ipamorelin?

Tesamorelin is a GHRH analog that targets the GHRH-R. Ipamorelin is a ghrelin-receptor agonist that targets GHS-R1a. Both increase GH release, but through different mechanisms.

Which has the most research?

Tesamorelin, by far. It has Phase III studies and is approved by the FDA for one indication. Ipamorelin has mainly been researched in animals.

Has the combination been studied?

No. There are no published controlled studies of tesamorelin and ipamorelin together. The rationale comes from general studies showing that GHRH analogs and GHRPs act synergistically.

Is ipamorelin approved by the FDA?

No. It has never been approved as a drug. Tesamorelin has only been approved to reduce abdominal fat in people with HIV.

References